MBTPS1 and Alzheimer disease: The beneficial effects of fingolimod in the AD context were attributed to central S1P modulation and downregulation of ceramide metabolism genes (Asle-Rousta et al., 2014; Joshi et al., 2017; Jęśko et al., 2020).